Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort.

Adult Antipsychotic Agents / adverse effects Case-Control Studies Cholinergic Antagonists / adverse effects Chronic Disease / epidemiology Comorbidity Depressive Disorder, Major / epidemiology Female France / epidemiology Humans Inflammation / epidemiology Male Risk Factors Schizophrenia / epidemiology Sexual Dysfunctions, Psychological / epidemiology Young Adult

Antipsychotics Inflammation Major depression Schizophrenia Sexual dysfunctions

Journal

Progress in neuro-psychopharmacology & biological psychiatry

ISSN: 1878-4216

Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry

Pays: England

ID NLM: 8211617

Informations de publication

Date de publication:
30 08 2019

Historique:

received: 08 02 2019

revised: 29 04 2019

accepted: 17 05 2019

pubmed: 28 5 2019

medline: 31 3 2020

entrez: 25 5 2019

Statut: ppublish

Résumé

Sexual dysfunctions (SD) are frequent in schizophrenia (SZ) and associated with treatment withdrawal, however they remain under-explored and under-treated. To date, most of the studies have focused on SD as antipsychotics' side effects in therapeutic trials. The objectives of the present study were to determine the SD prevalence in stabilized SZ outpatients and their clinical, pharmacological and biological correlates. Two hundred and thirty-seven participants (61.2% men) were consecutively included and received a thorough 2 days- clinical assessment including the self-reported Sexual Functioning Questionnaire (SFQ). SD was defined by a SFQ score ≥ 8. Two hundred and thirty-seven subjects were recruited in the FACE-SZ cohort, 41% of them reported sexual dysfunctions. In multivariate analyses, SD have been associated with current major depressive disorder (adjusted odd ratio aOR = 2.29[1.08-4.85], p = .03), anticholinergic prescription (aOR = 2.65, p = .02) and chronic low-grade inflammation (aOR = 2.09, p = .03) independently of age, gender, current cannabis use disorder and olanzapine prescription. No antipsychotic has been associated with increased or decreased SD rate. SD are frequent in SZ subjects. Major depression, anticholinergic prescription and chronic low-grade peripheral inflammation may be the three targets of interest for addressing this specific issue.

Sections du résumé

BACKGROUND

AIMS

The objectives of the present study were to determine the SD prevalence in stabilized SZ outpatients and their clinical, pharmacological and biological correlates.

METHOD

Two hundred and thirty-seven participants (61.2% men) were consecutively included and received a thorough 2 days- clinical assessment including the self-reported Sexual Functioning Questionnaire (SFQ). SD was defined by a SFQ score ≥ 8.

RESULTS

Two hundred and thirty-seven subjects were recruited in the FACE-SZ cohort, 41% of them reported sexual dysfunctions. In multivariate analyses, SD have been associated with current major depressive disorder (adjusted odd ratio aOR = 2.29[1.08-4.85], p = .03), anticholinergic prescription (aOR = 2.65, p = .02) and chronic low-grade inflammation (aOR = 2.09, p = .03) independently of age, gender, current cannabis use disorder and olanzapine prescription. No antipsychotic has been associated with increased or decreased SD rate.

CONCLUSIONS

SD are frequent in SZ subjects. Major depression, anticholinergic prescription and chronic low-grade peripheral inflammation may be the three targets of interest for addressing this specific issue.

Identifiants

DOI: 10.1016/j.pnpbp.2019.109654 PMID: 31125587

pubmed: 31125587

pii: S0278-5846(19)30113-7

doi: 10.1016/j.pnpbp.2019.109654

pii:

doi:

Substances chimiques

Antipsychotic Agents 0

Cholinergic Antagonists 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

109654